Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health.
Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health.
复制标题
DOI：
10.1016/j.biotechadv.2016.03.002
复制
发表时间：
2016-05
影响因子：
16
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Lan T;Zhang J;Lu Y
移动的网络和智能手机的最新进展为将体外诊断（IVD）从中心实验室转变为家庭或其他护理点（POC）提供了巨大的机会。实现该目标的一个主要挑战是与开发移动的健康（mHealth）中的POC IVD设备相关的长时间和高成本。我们和其他人没有为每个新的IVD目标开发新的POC设备，而是利用数十年来对血糖仪（BGM）的研究，开发，工程和持续改进，包括那些已经与智能手机集成的血糖仪，并将BGM转变为用于广泛生物标志物，治疗药物和其他分析目标的POC IVD的通用医疗保健仪。在这篇综述中，我们总结了通过抗体、DNA/RNA适体、DNAzyme/核酶和蛋白酶将靶的选择性结合扩增成可以通过商业上可获得的BGM测量的信号（例如葡萄糖或NADH）的方法，使得有可能适应在中心实验室进行的许多临床测定，例如免疫测定、适体/DNAzyme测定、分子诊断测定、和酶活性测定到BGM平台上，用于定量mHealth中各种IVD的非葡萄糖靶点。
Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.